Project Partners

*Coordinating and managing participants 

​Small/medium sized enterprise (SME)

AstraZeneca

Lund University

University of Dundee

University of Oxford

University of Gothenburg

University of Edinburgh

Boehringer Ingelheim

Sanofi-Aventis Deutschland GmbH

Helmholtz Zentrum Muenchen

F. Hoffmann-La Roche Ltd

Università di Pisa

Università di Firenze

University of Turku

University of Cambridge

Università degli Studi di Padova

Pfizer

University of Exeter

Instituto di Ricerche Farmacologiche “Mario Negri”, Bergamo

Karolinska Institute

Folkhälsan, Helsinki

The National Institute for Health and Welfare, Finland

Eli Lilly Ltd

Biocomputing Platforms Ltd

Università Cattolica del Sacro Cuore, Rome

Università degli Studi di Pavia

University of Eastern Finland

MISSION

To DISCOVER, DEVELOP and QUALIFY potential MARKERS that empower:

  • the identification of patients at high risk of diabetes complications

  • the monitoring of the complications' progression and patients‘ response to therapy 

To use the discovered markers as SURROGATE ENDPOINTS in clinical trials.



Thereby, SHORTEN the long lasting CLINICAL TRIALS to bring about EARLIER availability of NEW THERAPY to diabetic patients.

Related Sites